TRV-2026-1025Version 1 · Certified
Reason for this version
Certified into the record
Canonical text (the exact bytes fingerprinted)
TRUVACE RECORD VERSION record: TRV-2026-1025 version: 1 kind: certified reason: Certified into the record timestamp: 2026-09-09T06:05:30.965077Z status: published lens: trace sector: health headline: An integrative clinical-molecular model as an auxiliary predictive tool for glioma malignancy grade dek: Objective An integrative auxiliary predictive model incorporating clinical parameters, serum biomarkers, and molecular pathological markers was developed to assess glioma malignancy grade. Methods This single-center retrospective observational study consecutively enrolled 400 glioma patients. A total of 26 variables, including demographic characteristics, clinical parameters, laboratory indicators, and serum biomarkers, were analyzed. Predictors were selected using univariate analysis, followed by Least Absolute… gain_title: A Random Forest model integrating age, KPS, tumor diameter, NLR, AGR, IDH status and Ki-67 achieved AUC 0.864 training and 0.820 validation to assist preoperative assessment of high-grade glioma. problem_title: The auxiliary model cannot replace pathological and molecular diagnosis and relies on tissue-derived IDH and Ki-67 markers, with development limited to a single-center retrospective cohort of 400 patients and internal validation only. trace_subject: preoperative prediction of high-grade glioma (WHO III-IV) using integrative clinical-molecular Random Forest model gain_reading: A Random Forest model integrating age, KPS, tumor diameter, NLR, AGR, IDH status and Ki-67 achieved AUC 0.864 training and 0.820 validation to assist preoperative assessment of high-grade glioma. gain_evidence: The Random Forest achieved an AUC of 0.864 (95%CI: 0.815-0.914) in the training set and 0.820 (95%CI: 0.732-0.909) in the validation set. | This exploratory auxiliary tool can assist preoperative assessment and guide individualized treatment strategies problem_reading: The auxiliary model cannot replace pathological and molecular diagnosis and relies on tissue-derived IDH and Ki-67 markers, with development limited to a single-center retrospective cohort of 400 patients and internal validation only. problem_evidence: it cannot replace pathological and molecular diagnosis, as it incorporates tissue-derived markers such as IDH mutation status and Ki-67 index. | This single-center retrospective observational study consecutively enrolled 400 glioma patients. quick_read: On 2026-09-08, a peer-reviewed study reported development of an integrative clinical-molecular model for glioma malignancy grading using 400 patients from a single-center retrospective cohort. Using LASSO and machine learning, the authors built a Random Forest classifier based on seven predictors including age, KPS, tumor diameter, inflammatory ratios, IDH status and Ki-67, achieving AUC 0.864 in training and 0.820 in validation. The result matters because accurate preoperative grading can inform surgical planning and individualized therapy, and the model showed good calibration and net benefit across threshold probabilities 0.2-0.8. Uncertainty remains because validation was internal only, the design was retrospective and single-center, and the model itself requires tissue-derived molecular markers, so it cannot substitute for standard pathological diagnosis. limitation: Model is exploratory, single-center retrospective with internal validation only, and cannot replace pathological and molecular diagnosis because it depends on tissue-derived markers IDH and Ki-67. tag: Dual reading key_points: Single-center retrospective study of 400 glioma patients analyzed 26 clinical, laboratory and serum biomarker variables. | LASSO regression and machine learning selected 7 independent predictors including age, KPS score, maximum tumor diameter, neutrophil-to-lymphocyte ratio, albumin-to-globulin ratio, IDH mutation status and Ki-67 index. | Random Forest model showed excellent calibration with Hosmer-Lemeshow test p > 0.05 and clinical net benefit on decision curve analysis within 0.2-0.8 threshold probability range. rundown: The study consecutively enrolled 400 glioma patients and evaluated 26 variables spanning demographics, clinical parameters, laboratory indicators and serum biomarkers. Univariate analysis followed by LASSO regression identified predictors, with SHAP analysis used for interpretability and AUC, calibration curves and decision curve analysis for performance. Independent predictors for WHO grades III-IV included age OR 1.085, KPS OR 0.928, maximum tumor diameter OR 1.649, neutrophil-to-lymphocyte ratio OR 2.310, albumin-to-globulin ratio OR 0.163, IDH wild-type vs mutant OR 4.502, and Ki-67 OR 1.176. The authors position the model as an auxiliary preoperative tool that still requires tissue diagnosis. sources: - peer_reviewed | Neurological Research | https://doi.org/10.1080/01616412.2026.2730581 | 2026-09-08 prev: 0000000000000000000000000000000000000000000000000000000000000000
- sha256
- cdf20d9265c6beb77b4a532fabb8b054da98236ac6f5f11fffb379f292241e7e
- previous
- 0000000000000000000000000000000000000000000000000000000000000000
Verify this record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-1025 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.
ace